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Abstract
Degenerative disorders of joints, especially osteoarthritis (OA), result in persistent pain and disability and high costs
to society. Nevertheless, the molecular mechanisms of OA have not yet been fully explained. OA is characterized by
destruction of cartilage and loss of extracellular matrix (ECM). It is generally agreed that there is an association
between pro-inflammatory cytokines and the development of OA. There is increased expression of matrix
metalloproteinase (MMP) and “a disintegrin and metalloproteinase with thrombospondin motifs” (ADAMTS).
Mesenchymal stem cells (MSCs) have been explored as a new treatment for OA during the last decade. It has been
suggested that paracrine secretion of trophic factors, in which exosomes have a crucial role, contributes to the
mechanism of MSC-based treatment of OA. The paracrine secretion of exosomes may play a role in the repair of
joint tissue as well as MSC-based treatments for other disorders. Exosomes isolated from various stem cells may
contribute to tissue regeneration in the heart, limbs, skin, and other tissues. Recent studies have indicated that
exosomes (or similar particles) derived from MSCs may suppress OA development. Herein, for first time, we
summarize the recent findings of studies on various exosomes derived from MSCs and their effectiveness in the
treatment of OA. Moreover, we highlight the likely mechanisms of actions of exosomes in OA.
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Introduction
Osteoarthritis (OA), one of the most common musculo-
skeletal diseases, is characterized by sub-chondral bone
sclerosis, synovial inflammation, cartilage degradation,
ligament calcification, and osteophyte formation [1, 2].
Damage to joints following trauma, obesity, age, and
genetic background are the major risk factors for OA
[3]. OA leads to extensive public health costs for treat-
ment and prevention, and a considerable loss of eco-
nomic productivity due to worker incapacity [4, 5]. The
direct cost of OA in the Canada, USA, UK, Australia,
and France accounts for 1–2.5% of the gross national
product of country; however, the indirect cost of OA are
much higher, and it seems the true cost of OA is under-
estimated [5]. Direct costs are accounted for hospital
stays, surgery, diagnosis, health professional visits, and
treatments [5]. The indirect costs are those paid and un-
paid activities, like employment, schooling, and home-
making, that result from disability associated with the
health status [5]. Since the prevalence of OA rising with
age, in an aging population, the OA is a growing source
of indirect costs [5].
Currently, the treatments are mainly directed to relieving
the symptoms of OA using non-steroid anti-inflammatory
drugs (NSAID) and painkillers [6]. Because the mentioned
drugs are not very effective, cannot ameliorate the disease
and its symptoms for long periods of time, and also have
many side effects [7], the search for novel therapeutic strat-
egies is an important issue [8].
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Mesenchymal stem/stromal cell (MSC)-based therapy
is a promising new approach for OA, which has been
further developed in recent years [9–13]. Preclinical
studies have indicated that the cartilage of the joint can
be protected from degeneration, and the development of
OA can be delayed through intra-articular injection of
MSCs isolated either from adipose tissue or from bone
marrow [14–17]. Furthermore, some clinical trials have
evaluated MSC-based treatments for OA and have
shown decreases in inflammation and pain [12]. In a
phase I–II clinical trial, Soler and colleagues have uti-
lized ex vivo expanded autologous mesenchymal stromal
cells for the treatment of osteoarthritis of the knee aim-
ing to assess their safety and cartilage regeneration cap-
acity. Their results showed that this cell-based therapy
was well tolerated, though some adverse effect events
(e.g., mild arthralgia and low back pain) were reported.
There was a significant decrease in the intensity of pain
since day 8 after the cell product administration and that
was lasted after 12 months. The SF-36 QoL assay exhib-
ited improvement of factors including bodily pain and
physical functioning at month 12. The health assessment
questionnaire showed a substantial decrease of disability.
T2 mapping of cartilage also revealed signs of tissue re-
generation in all patients at 12 months post-therapy [18].
In another study, Matas et al. have evaluated the safety
and therapeutic efficacy of the single or repeated intraar-
ticular administration of umbilical cord-derived (UC)
MSCs in the knee of OA patients(a phase I/II trial) [19].
No severe adverse events were observed. MSC-treated
patients showed more significant pain and greater func-
tion improvement from baseline. At 12 months, based
on Western Ontario and Mc Master Universities Arth-
ritis Index, MSC-treated patients (MSC-2 group) signifi-
cantly experienced lower levels of pain versus the
hyaluronic acid (HA) group. Visual analog scale for the
pain and total Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) were also consid-
erably lower in the MSC-2 group compared with the HA
group at 12 months post-therapy [19].
MSCs may secrete mediators with chondro-protective
and anti-inflammatory activities contributing to thera-
peutic impacts [20, 21].
MSC-derived extracellular vesicles (EVs) are a mixed
population of heterogeneous membranous vesicles with
distinct content which are critical mediators of intercel-
lularcommunication. These vesicles establish a vesicle-
mediated transport system to regulate a wide range of
biological and pathological processes [22]. They are in-
volved in cell-to-cell communication pathways [23]. The
three major categories of EVs are (a) apoptotic bodies,
(b) microparticles or microvesicles, and (c) exosomes or
nanovesicles [24]. EVs are specified by their dimensions,
expression of membrane markers, and their biogenesis.
The endosomal compartments in multivesicular bodies
are involved in producing exosomes. Endosomal markers
(CD9, CD61, CD83, ALIX, TSG101) are expressed by
exosomes, whereas microparticles (MPs) are released by
a cell membrane budding process. It should be noted
that MPs express markers according to their parental
cells [2].
The crucial role of MSC-derived exosomes for the
regulation of cell migration, proliferation, differentiation,
and extracellular matrix synthesis has been increasingly
supported by recent findings [25–27]. A report in 2010
showed that exosomes are secreted as active factors by
MSCs responding to damage caused by myocardial is-
chemia reperfusion (I/R) [28]. Moreover, reports have
demonstrated that MSC exosomes contribute to the re-
pair and regeneration of cartilage via regulating immune
reactivity, diminishing apoptosis, and increasing prolifer-
ation [29–31]. Exosomes, which function as intercellular
communication vehicles, are small lipid-bilayer mem-
brane vesicles between 50 and 150 nm in diameter [32].
Exosomes are able to transfer cargos of nucleic acids
(mRNAs and microRNAs), proteins, and bioactive lipids
[32]. Exosomes can produce biological responses in re-
cipient cells [28]. Some findings have shown ambiguous
effects of exosomes on the immune response or possible
tumorigenicity, which may be considered unfavorable
properties of exosomes [33, 34]. Nevertheless, there have
been few studies conducted to investigate the precise
molecular mechanisms by which MSC exosomes can
promote cartilage chondrogenesis [27, 31, 35–37].
Recently, numerous investigations have been carried out to
evaluate the potential role of exosomes derived from stem
cells isolated from different sources. An in vivo study re-
vealed that symptoms of OA could be decreased by exo-
somes isolated from iPS-derived MSCs, or from synovial
MSCs; however, the highest efficiency was seen for exosomes
from iPS-derived MSCs [38]. However in some studies, stem
cells did not have a good therapeutic benefit in the treatment
of OA. Tao and colleagues showed that the anabolic activity
of chondrocytes was decreased by MSC-derived exosomes,
unless the MSCs had been engineered to express miR-140-
5p [39]. Also, the beneficial effects of embryonic stem cell-
derived exosomes have been reported in a model involving
destabilizing the medial meniscus (DMM) [36]. As yet, there
is no information about the effect of other kinds of EVs on
OA. In this review, we summarize the pathogenic roles of
exosomes in OA, and the evidence for exosomes derived
from MSCs in the treatment of OA.
Exosomes: biogenesis, cargos, and different
subtypes
Biogenesis of exosomes
Exosomes have dimensions ranging between 30 and 150 nm.
They are nanoscale EVs that are produced by nearly all types
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of cells [40, 41]. Exosomes are produced by the endosomal
network, via intra-luminal vesicles (ILV, also known as pre-
exosomes) formed by inward budding of the membranes of
multivesicular bodies [40, 42]. Numerous different pathways
[43], such as ESCRT (endosomal sorting complexes required
for transport), and ESCRT-independent pathways are in-
volved in exosome biogenesis (Fig. 1). Exosome biogenesis
requires four separate multiprotein sub-complexes (ESCRT-
0, ESCRT-I, ESCRT-II, and ESCRT-III) that compose the
ESCRT membrane-scission machinery. Ubiquitinated pro-
teins are bound in initial ESCRT complexes (ESCRT-0,
ESCRT-I, and ESCRT-III) via their ubiquitin-binding sub-
units, which result in the formation of strongly bound com-
plexes with proteins in the cytoplasm. The ESCRT-III com-
plex temporarily assembles on the endosome membrane and
undergoes vesicle scission [44]. It has been found that
additional components, such as apoptosis-linked gene 2
(ALG-2)-interacting protein X (ALIX) (a cytoplasmic protein
concentrated and expressed in exosomes and phagosomes),
ATPase, and vacuolar protein sorting-associated protein
(VPS4) are involved in regulating the ESCRT membrane-
scission machinery [44]. Moreover, lipids such as the sphin-
golipids, ceramide [45, 46], and sphingosine 1-phosphate
function in the ESCRT-independent pathway to regulate the
release of exosomes [47].
Cargos of exosomes
The molecular components of exosomes, including
lipids, nucleic acids, metabolites, and proteins, differ
from each other, based on the cellular origin, environ-
ment, developmental phase, epigenetic modification, and
the precise biogenesis mechanism. Moreover, studies
have identified a variety of RNA types, such as micro-
RNAs (miRNAs), messenger RNAs (mRNAs), transfer
RNAs (tRNAs), long noncoding RNAs (lncRNAs), or
ribosomal RNAs (rRNAs) that all can be present in
Fig. 1 Exosome biogenesis and its relationship with osteoarthritis. A clathrin-dependent pathway or a clathrin-independent pathway initially
mediates endocytosis, at a lipid raft. The endocytic vesicles contain signaling proteins, growth factor receptors, oncoproteins, combined with
normal membrane proteins, including tetraspanins (e.g., CD9, CD63, and CD81), MHC I and II, and adhesion molecules (e.g., cadherins, integrins).
Exosome biogenesis occurs via the endosomal network in the endosomal sorting complexes needed for ESCRT-independent or ESCRT-
dependent pathways. Inward budding of MVB produces intra-luminal vesicles (exosomes). Several cytoplasmic molecules (e.g., heat shock
proteins, ubiquitin-related proteins, mRNAs, microRNAs [miRNAs], cytoskeleton proteins) and nuclear molecules (e.g., long-noncoding RNAs
[lncRNAs], transcriptional factors, DNAs) can be loaded into MVB by stage-specific pathways, some of which are osteoarthritis type-specific.
Moreover, plasma membrane fusion of multi-vesicular bodies leads to release of exosomes by exocytosis. Numerous Rab GTPases (such as Rab11/
35, Rab7, and Rab27) are present in secreted exosomes. Eventually, MSC-derived exosomes are transported to the osteoarthritis micro-
environment where they modulate osteoarthritis. ESCRT, endosomal sorting complexes required for transport; MHC, major histocompatibility
complex; MSCs, mesenchymal stem cells; MVB, multi-vesicular bodies; rER, rough endoplasmic reticulum; sER, smooth endoplasmic reticulum; Rab,
Ras-associated binding
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exosomes [48]. Different types of RNA cargo may be in-
volved in epigenetic modification of cells and altering
biological activities. Recent studies have indicated that
double-stranded DNAs (dsDNAs) found in tumor-
derived exosomes could reflect the mutational status of
their parental tumors [49]. Studies have shown that > 10
kb pieces of cellular genomic DNA are indicative of mu-
tations in oncogenes or tumor suppressor genes in
tumor-derived exosomes [50]. Furthermore, various bio-
active proteins, which originate from the plasma mem-
brane and the cytoplasm, exist within exosomes. Certain
proteins, including Ras-related GTP-binding protein
(Rab), ALIX, or ESCRT complexes that participate in
exosome biogenesis, have been found in exosomes [44].
Additional proteins, including tetraspanins (i.e., CD9,
CD63, and CD81), heat shock proteins (e.g., HSP70 or
HSP 90), and integrins, can be packaged into exosomes,
which are involved in intracellular assemblage or traf-
ficking [40]. The expression patterns of proteins which
reflect the pathophysiological status of the parental cells
can be determined by analysis of exosomal proteins. The
composition of the membranes of exosomes is charac-
teristic of lipid rafts. They contain larger amounts of
particular lipid species, such as sphingomyelin, phos-
phatidylcholine, cholesterol, ceramide, and diacylglycerol
in comparison with their parental cells [51]. The release
and formation of exosomes are regulated by lipid-
metabolizing enzymes, such as phospholipase D2 (PLD2)
or neutral sphingomyelinase (nSMase) [45].
Subtypes of exosomes
Most researchers, who have investigated exosome-
mediated cell functions, have used heterogeneous exo-
some preparations with different molecular cargos,
and varying dimensions and morphology, all resulting
in different biophysical properties. These have in-
cluded large exosome vesicles (90 to 120 nm), small
exosome vesicles (60 to 80 nm), and non-membranous
nanoparticles (also known as exomeres, size about 35
nm) [52]. Glycomic, lipidomic, and proteomic analyses
have shown different molecular profiles inside exo-
somes and exomeres. Proteomic analysis has shown a
higher expression of enzymes associated with metabol-
ism, hypoxia, and microtubule and coagulation-related
proteins in exomeres, in comparison with large or
small membranous exosomal vesicles. On the other
hand, large and small exosomal vesicles contain higher
amounts of signaling proteins associated with the mi-
totic spindle, interleukin (IL)-2/STAT5, and proteins
associated with endosome secretion pathways [52].
Differences between exomeres and exosomes also in-
volve sialylated glycoproteins (i.e., galectin-3-binding
protein) [52]. Because there are differences in the lipid
composition between different exosomes (and also
exomeres) [52], density gradient centrifugation can
separate them into two distinguishable populations:
higher density exosomes (HD-Exo) and lower density
exosomes (LD-Exo) [53]. An increase in “solute carrier
family 38 member 1” (SLC38A1) was demonstrated in
LD-Exo-treated endothelial cells in comparison with
HD-Exo-treated endothelial cells [53]. Overall, studies
have indicated that different biological effects can be
triggered on recipient cells by using different exoso-
mal sub-populations.
Exosomes and osteoarthritis
mRNAs, proteins, long noncoding RNAs (lncRNA, cir-
RNA), and miRNAs are all found in the exosomal con-
tents. Changes in gene expression, downstream function,
and processes related to physiology or pathology may be
caused by the action of exosomes on recipient cells [54].
Recently, some studies have been carried out to evaluate
the various effects of exosomes on different cells involved
in the joint diseases [23, 42, 55, 56]. Cell-derived EVs have
been isolated from synovial fibroblasts (SF) extracted from
the inflamed joints of OA and RA patients and investi-
gated their role in the cellular processes such as inflamma-
tion and cartilage degeneration which are implicated in
the disease progression [56–58]. Domenis et al. explored
the immune regulatory properties of SF-derived exosomes
from end-stage OA patients, on macrophages differenti-
ated from human peripheral blood mononuclear cells
(PBMCs) [59]. When patient cells were treated by exo-
somes, it was demonstrated that the macrophages gener-
ated a spectrum of chemokines and pro-inflammatory
cytokines, such as CCL8, IL-1β, MMP12, CCL15, MMP7,
and CCL20, which would result in cartilage degradation
and inflammation in joints [59]. Kolhe et al. performed
similar experiments and showed a significant decrease in
cell survival and the expression of anabolic genes
(COL2A1, ACAN), and an increase in the expression of
catabolic and inflammatory genes (IL-6, TNF-α) using ar-
ticular chondrocytes treated with exosomes derived from
SF from OA patients [60]. Kato et al. [61] investigated
whether exosomes mediated the interaction between ar-
ticular chondrocytes and inflammatory synovial fibroblasts
(SFBs). Exosomes were isolated from untreated similar
fragment pairs (SFBs) and from similar fragment blocks
(SFPs) that had been treated or not with IL-1β, and were
then added to normal articular chondrocytes. These
workers showed upregulation of the expression of MMP-
13 and ADAMTS-5 and downregulation of ACAN and
COL2A1 in articular chondrocytes when treated with IL-
1β-treated SFB-derived exosomes, compared to exosomes
from untreated SFBs. Additionally, exosomes from IL-1β-
treated SFBs produced OA-like changes in both in vitro
and in vivo models.
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Two studies carried out comparisons between exo-
somes from various sources for discovering arthritis
mechanisms. SF exosomes from patients with RA and
OA were compared by Zhang et al. They observed a
membrane-bound form of TNF-α in exosomes generated
from SF of patients with RA; however, they did not see
this phenomenon in the case of OA. Moreover, another
research found that this kind of TNF-α enhances SFB
exosome generation in RA and forms a positive amplifi-
cation loop in RA pathogenesis [62].
Kolhe et al. compared SF-derived exosomes isolated
from females and males with OA and non-OA in order
to examine sex differences in OA pathophysiology. They
observed a difference in the miRNA contents of EVs be-
tween groups with OA and non-OA, as well as between
the two sexes [60]. The “Kyoto Encyclopedia of Genes
and Genomes” (KEGG) represents a comprehensive
database which is used to map associated genes to their
respective pathways [63]. Though pathway maps, the
KEGG pathway database provides pathway diagrams in
both healthy and diseased states [64]. KEGG annotation
analysis was used to assess the relationship between gly-
can degradation, cell adhesion molecules, and mucin
type O-glycan biosynthesis and downregulated miRNAs
in OA for each sex. Moreover, the possible involvement
of thyroid hormone synthesis, biotin metabolism, and
signaling related to amphetamine addiction was investi-
gated along with upregulated miRNAs. Contributions
from ovarian steroidogenesis and estrogen signaling
pathways were also detected using KEGG annotation
analysis in female OA patients [60]. Table 1 shows exo-
somes and their cargos involved in arthritis.
MSC-derived exosomes and OA
There has been ever-increasing interest in the clinical
application of MSCs for a variety of diseases in recent
years. MSCs have been widely studied for their potential
to treat joint damage and OA [27, 79–83]. The MSCs
have usually been isolated from synovium [84], bone
marrow [85], and adipose tissue [21]. Researchers have
assessed the effectiveness of MSCs in restoration of
damaged tissue function or alleviate disease symptoms
in OA or cartilage damage [86, 87]. For example, the
safety and tolerability over the medium-term (~ 5 years)
of intra-articular injection of MSCs has been shown for
the treatment of knee in the OA in phase I and II clin-
ical trials. This success has led to the reduction of pain
and enhancement of joint performance and improved
quality of cartilage repair [88–90].
It has been revealed that MSC-derived exosomes could
protect cartilage and bone from degradation in OA by in-
creasing the expression of chondrocyte markers like type
II collagen and aggrecan, reducing catabolic markers such
as MMP-13 and ADAMTS5, decreasing inflammatory
markers (iNOS), protecting chondrocytes from apoptosis,
and blocking of macrophage activation [2]. Furthermore,
it has been exhibited that MSC-derived exosomes could
attenuate OA by stimulation of chondrocyte migration
and proliferation [38].
The motivation for transplantation of MSC for treat-
ment of joint diseases is based on their potential for
multi-lineage differentiation into mesenchymal cell types
(e.g., bone, cartilage, and fat tissues) which are all essen-
tial for musculoskeletal repair. Of course, treatment with
allogeneic MSC is relied on the lack of evoking an im-
mune response [90]. Nevertheless, numerous researchers
have found that in spite of the functional enhancement
(or even the regeneration of joint tissue) which was ob-
served following transplantation of MSCs into diseased
joints, their engraftment and subsequent differentiation
into the desirable cell types only occurred only rarely
[91]. The paracrine function of the MSCs has been sug-
gested to explain these observations, with the hypothesis
that MSCs principally execute their therapeutic effect
through the secretion of trophic factors that improve re-
generation and decrease inflammation [92]. In the next
section, the promising role of MSC-derived exosomes in
the mitigation of inflammation in the OA is discussed in
detail.
MSC-derived exosomes and their anti-inflammatory
effects in OA
Although OA is commonly regarded as a degenerative
disease, recent work has proposed that low-grade in-
flammatory processes are able to induce disease symp-
toms and promote the progression of disease [93].
Hence, immunomodulatory function of MSCs should be
further considered. MSCs are able to promote the regen-
eration of joint components through their two secretory
functions as follows:
a. Anti-inflammatory factors. MSCs may
downregulate inflammatory signals in osteoarthritic
cartilage, by secretion of interleukin (IL)-1β, IL-6,
IL-8, matrix metalloproteinase (MMP)-1, and
MMP-13 [94, 95].
b. Trophic factors. These are molecules that give rise
to cell proliferation, decrease formation of scar
tissue, and trigger the repair of endogenous
cartilage, such as epithelial growth factor (EGF),
insulin-like growth factor (IGF)-1, basic fibroblast
growth factor (bFGF), transforming growth factor
(TGF)-β, and vascular endothelial growth factor
(VEGF) [94, 96].
Although there is much evidence for the ability of
MSCs to heal damage to joints, and to treat OA, there
are several problems with the approach of direct cell
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Table 1 Exosomes and their cargos in arthritis
Disease Composition of exosome cargo Model Sample (n) Function(s) Ref
RA, OS Fn (α, β chain), FGB, fibrinogen D
fragment, Spα, α2M, IgG1 γ-chain
C region, Fn/IgG complex
Human 15 Induction of T cells, enhancement of T cell immunity,
Inhibition of TNF, antigen presentation
[65]
RA Integrin CD41 Human Not mentioned – [66]
RA LYVE-1 ↑ Human 60 Lymphangiogenesis [67]
AA AA tended to be higher in patients with higher
disease activity
RA TNF-α Human 10 Induction of apoptosis resistance in CD4+ T cell
via sustaining the activities of both Akt and NF-
κB, and blocking some effects of caspase activation
[62]
Collagen-induced arthritis CD71, HSP70 Mice 2 Immunosuppressive and anti-inflammatory effects [68]
RA MHC I and II molecules,
CD11c, CD86, CD178
Mice – Immunosuppressive and anti-inflammatory effects [69]
Collagen-induced arthritis HSC70, CD81, CD80/86,
MHC I, and MHC II
Mice 2 Immunosuppressive and anti-inflammatory effects [70]
RA, PsA Rank in PA↓, in RA↑ Human 22 Modulation of the osteoclastogenesis [71]
OA hsa-miR-4717-5p ↑ Human 6 Modulation of the RGS2 [72]
RA miR-17 ↑ Human 25 Regulation of Treg differentiation by inhibiting TGFBR
II expression and disrupting the homeostasis of Tregs.
[73]
RA miR-6089 ↓ Human 76 Regulation of IL-6, IL-29, and TNF-α production by
targeting LPS/TLR4-mediated inflammatory response
[74]
RA miR-548a-3p ↓ Human 76 Inhibition of proliferation and activation by regulating
the TLR4/NF-κB signaling pathway
[75]
OS Different types Human 41 Estrogen responsive in female osteoarthritis and targeting
TLR signaling pathways
[60]
RA miR-221-3p ↑ Mice 30 Inhibition of osteoblast differentiation by suppressing the
expression of Dkk2 and regulation of signaling pathways
at erosion sites that affect bone loss and compensatory
bone formation
[76]
OA PCGEM1 ↑ Human 42 Triggering proliferation of osteoarthritic synoviocytes and
progression of OA
[77]
RA Hotair↑ Human 28 Activation of MMP-2 and MMP-13 in osteoclasts and RA
synoviocytes and leading to migration of active macrophage
[78]
LUST↑
anti-NOS2A↑
MEG9↑
TUG1↑
NEAT1↑
SNHG4↑
Malat1↓
SNHG1↓
PR antisense↓
mascRNA↓
PRINS↓
transcripts↓
HOXA3as↓
OA Not mentioned Human 10 Stimulation of M1 macrophages to release IL-1β/ IL-16, CCL20/
CCL15/CXCL1) and MMP12/MMP7
[59]
AA amyloid A, anti-NOS2A anti-nitric oxide synthase 2 A, CCL20 chemokine (C-C motif) ligand 20, CD41 cluster of differentiation 41, Dkk2 Dickkopf-related
protein 2, Fn fibrin, Hotair HOX Transcript Antisense RNA, HOXA3 Homeobox A3, HSC70 heat shock cognate protein 70, HSP70 heat shock protein70, IL-6
interleukin 6, LPS/TLR4 lipopolysaccharide/Toll-like receptor 4, LUST Luca-15-specific transcript, LYVE-1 lymphatic vessel endothelial hyaluronan receptor 1,
mascRNA MALAT1-associated small cytoplasmic RNA, Malat1 metastasis-associated lung adenocarcinoma transcript 1, MEG9 maternally expressed 9, MMP-2
matrix metallopeptidases-2, MHC I and II major histocompatibility complex I and II, NEAT1 nuclear enriched abundant transcript 1, NF-κB nuclear factor
kappa-light-chain-enhancer of activated B cells, OA osteoarthritis, PRINS psoriasis-susceptibility related RNA gene induced by stress, PsA psoriatic arthritis, RA
rheumatoid arthritis, Rank receptor activator of nuclear factor kappa-B, RGS2 regulator Of G protein signaling 2, SNHG4 small nucleolar RNA host gene 4,
Spα surface plasmon alfa, TNF tumor necrosis factor, TUG1 taurine upregulated gene 1
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transplantation, such as the poor survival of the cells
after injection, the inability to predict lasting improve-
ments in cell behavior and cell-cell interactions, and
problems in maintaining an adequate storage bank of
cells to allow off-the-shelf treatment [97]. The suitability
of donors may be another important challenge, because
it was found that MSCs isolated from old or otherwise
unhealthy donors led to decreased performance and pro-
liferation [98]. Moreover, the induction of senescence,
loss of proliferative potential, and reduced capacity for
differentiation (particularly beyond 10–20 population
doublings) have been attributed to prolonged ex vivo cell
expansion of MSCs before transplantation [98]. Because
of their genetic programming to undergo calcification
after chondrogenic induction as part of the normal
process of endochondral ossification, there are problems
in maintaining the cartilage phenotype in differentiated
MSCs and preventing them from expanding towards the
osteogenic phenotype [99]. Moreover, MSCs are sensi-
tive to certain “environmentally responsive” factors and
undergo specific behavioral modification in response to
minute traces of unknown substances in the microenvir-
onment [96]. Although this responsiveness is frequently
utilized in regenerative medicine, it can have a negative
impact on the MSC response in a diseased joint environ-
ment. For example, reports have demonstrated that hu-
man adipose tissue-derived MSCs can switch to a pro-
inflammatory secretome, when treated with tumor ne-
crosis factor (TNF), and can then play a role in aug-
menting the inflammatory response [100]. Therefore,
current studies have focused on testing the secretory
products of MSCs, including MSC-derived exosomes in
experimental models of joint damage and OA, rather
than transplanting the cells themselves.
There are many similarities between the biological ef-
fects of stem cell-derived EVs and the intact stem cells
themselves. However, stem cell-derived EVs have advan-
tages (e.g., small dimensions, low immunogenicity, and
elimination of procedural issues related to direct cell in-
jection). EVs were first described as “platelet dust” in the
1960s [101] and have been intensely investigated by re-
searchers during the past decades. EVs are now realized
to be powerful intercellular messengers that not only
can mediate pathological processes, but can also main-
tain tissue homeostasis, and can modulate physiological
functions in a variety of therapeutic approaches [102,
103]. They have been studied as anti-tumor treatments,
to improve vaccination against pathogens, as immuno-
modulatory treatments, as drug delivery vectors, and to
improve regenerative therapies [104]. Although several
studies have been conducted on the use of stem cell-
derived EVs as a treatment for joint damage and OA,
there is still a lack of hard evidence [23, 58]. However,
there are a few studies on this emerging and novel topic,
suggesting the powerful ability of stem cell-derived EVs
to improve joint repair and protect joints from degener-
ation after damage (Table 2).
Zhu et al. carried out a comparative study between exo-
somes derived from synovial membrane MSCs (SMMSC-
Exos) and exosomes derived from induced pluripotent
stem cell-derived MSCs (iMSC-Exos) to treat OA [38].
These researchers showed that the diameter of both
SMMSC-Exos and iMSC-Exos was between 50 and 150
nm. These exosomes expressed TSG101, CD9, and CD63.
Injection of both SMMSC-Exos and iMSC-Exos into a
murine OA model reduced symptoms of OA; however, a
greater therapeutic impact was achieved with iMSC-Exos
compared to SMMSC-Exos. Both SMMSC-Exos and
iMSC-Exos triggered the proliferation and migration of
chondrocytes. Overall, they showed a higher therapeutic
impact of iMSC-Exos in comparison with SMMSC-Exos
[38, 114]. Since autologous iMSCs can be more readily ob-
tained, they may provide a new treatment procedure for
OA [38].
Zhang et al. evaluated the contribution of MSC exo-
somes to regulate the inflammatory response, nocicep-
tive behavior, condylar cartilage, and subchondral bone
preservation in an immunocompetent rat model of tem-
poromandibular joint osteoarthritis (TMJ-OA) [109].
These researchers showed that there was an initial inhib-
ition of pain and degeneration with decreased inflamma-
tion, accompanied by a strong proliferation and gradual
enhancement in matrix expression and the architecture
of the subchondral bone, which demonstrated an overall
joint repair and reconstruction. Chondrocyte culture can
be used to assess cellular activities during exosome-
mediated joint repair, measuring adenosine signaling
and the activity of AKT, ERK, and AMPK. MSC-derived
exosomes increased s-GAG synthesis that had been
inhibited by IL-1β, and reduced IL-1β-induced nitric
oxide and MMP13 production. Inhibitors of adenosine
receptor activation and AKT, ERK, and AMPK phos-
phorylation partly reduced these effects. Overall, Zhang
et al. observed increased TMJ restoration and recon-
struction in OA, via a mechanism mediated by MSC
exosomes. This mechanism involved several cellular pro-
cesses involving repair of the matrix and general joint
homeostasis. The researchers suggested this was a cell-
free, ready-to-use exosome-based therapy to treat TMJ
pain and degeneration [109].
Therapeutic potentials of MSC-derived exosomes from
different cell origins in OA
The cargo of exosomes derived from various cell types is
highly heterogeneous and comprised of different bio-
logical molecules such as proteins, nucleic acids, and
lipids that not only show the cell origin of exosomes, but
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also reflect the pathological or physiological conditions
of the cell of origin [115, 116].
MSC-derived exosomes take part in intercellular commu-
nications and also deliver various miRNAs, mRNAs, and
proteins into recipient cells, in a similar manner to exo-
somes derived from other cells [97]. Up to now, more than
150 miRNAs and 850 unique gene products have been rec-
ognized in MSC-derived exosomes [117, 118]. Prior studies
have shown that, depending on the MSC source, the func-
tion and phenotype of MSC-derived exosomes may vary
[119]. By utilizing RNA sequencing and comparative ana-
lysis, it has been shown that the content of exosomes de-
rived from MSCs of human adipose tissue and bone
marrow has significant differences in their composition, like
certain tRNA species (Nanog, POU5F1A/B, and Sox2 ex-
pression), which seems to be correlated with the differenti-
ation status of MSCs and their cell of origin [119, 120]. The
therapeutic properties of human MSCs derived from adi-
pose tissues, bone marrow, and endometrium have been re-
cently compared in an experimental model of myocardial
infarction [121]. The findings revealed the superior cardio-
protection with endometrial MSCs compared to adipose
and bone marrow-derived MSCs [121]. These data suggest
that intrinsic differences among exosomes derived from
MSCs isolated from different cellular sources should be
considered as these differences may have profound impact
on therapeutic outcomes [121].
The degeneration of cartilage tissue during OA progres-
sion is caused by chronic inflammation. Adipose tissue-
derived MSCs (AD-MSCs) have the potential to blunt de-
generative and inflammatory processes in OA. These cells
also showed a paracrine effect on chondrocytes. Tofiño-Vian
et al. have revealed that EVs isolated from human AD-
MSCs exerted chondroprotective functions through multiple
Table 2 Exosome derived from various types of stem cells and arthritis
Cargo Composition
of cargo
Type of
arthritis
Type of
stem cell
Model Function Ref
Protein CD9, CD63,
and TSG101
OA SMMSC
and
iMSCs
Mice Induce the chondrocyte migration and proliferation [38]
Non-
coding
RNA
miR-92a-3p OA MSCs Mice Modulate the development of cartilage and homeostasis
via direct targeting and inhibition of WNT5A
[37]
miR-320c OA hBMSCs In
vitro
Downregulate the MMP13 and up regulate SOX9)expression [105]
miR-140-5p OA SMSCs Rat Improve the proliferation and migration of articular chondrocytes and prevent
OA
[90]
miR-150-5p RA MSCs Mice Decrease joint destruction though inhibiting the synoviocyte hyperplasia and
angiogenesis
[106]
lncRNA-KLF3-
AS1
OA MSCs Rat Inhibit IL-1β-induced apoptosis of chondrocytes [107]
Not
mentioned
Not
mentioned
OA MSCs Rabbit Inhibit the phosphorylation of p38 and ERK and induces the phosphorylation
of Akt
[108]
Not
mentioned
Not
mentioned
OA MSCs Rat Improve the synthesis of s-GAGOmpedes by IL-1β, and inhibits the IL-1β-
induced nitric oxide and MMP13 production
[109]
Not
mentioned
Not
mentioned
OA AD-MSCs In
vitro
Decrease the generation of inflammatory mediators such as TNF-α, IL-6, PGE2,
and NO and improve the generation of the anti-inflammatory cytokine IL-10
[110]
Not
mentioned
Not
mentioned
OA AD-MSCs In
vitro
Downregulate the SABG activity and. Reduce the generation of inflammatory
mediators.
[111]
Not
mentioned
Not
mentioned
OA BM-MSCs Mice Induce the type II collagen, and aggrecan expression, inhibit the expression of
the MMP-13, ADAMTS5, and iNOS
[2]
Not
mentioned
Not
mentioned
OA ESC-MSCs Mice Augment the synthesis of collagen type II and reduce the expression of
ADAMTS5 in the presence of IL-1β
[36]
Not
mentioned
Not
mentioned
Collagen-
Induced
Arthritis
MSCs Mice Anti-inflammatory role on T and B-lymphocytes [112]
Not
mentioned
Not
mentioned
Antigen-
induced
synovitis
MSCs Pig Reduce the synovial lymphocytes together with a down modulation of TNF-α
transcripts
[113]
ADAMTS5 A disintegrin and metalloproteinase with thrombospondin motifs 5, AD-MSCs adipose-derived MSCs, ESCs embryonic stem cells, ERK extracellular-signal-
regulated kinase, KLF3-AS1 KLF3 antisense RNA 1, IL-1β Interleukin 1 beta, iMSCs iPSC-derived MSCs, iNOS inducible nitric oxide synthase, hBM-MSCs human bone
marrow-MSCs, MMP13 matrix metalloproteinase-13, MSCs mesenchymal stem cells, NO nitric oxide, OA osteoarthritis, SMMSC synovial membrane, PGE2
prostaglandin E2, s-GAG sulfated glycosaminoglycan, SOX9 SRY-Box 9, RA rheumatoid arthritis, TNFα tumor necrosis factor alpha, TSG101 tumor susceptibility gene
101, WNT5A Wnt Family Member 5A
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mechanisms such as reduced the production of inflamma-
tory mediators (e.g., TNF-α, IL-6, PGE2 and NO), decreased
the release of MMP activity, and enhanced the production
of the anti-inflammatory cytokine IL-10 [110]. The authors
concluded that AD-MSC extracellular vesicles can be
employed for the development of new therapeutic ap-
proaches in joint conditions.
Researchers have comparatively evaluated the function of
exosomes or microvesicles/microparticles (MPs) in OA [2].
These researchers showed that there is no significant differ-
ence between function of exosomes and MPs derived from
BM-MSCs. They also found that treatment with both
exosomes and MPs derived from BM-MSCs can not only
restore the expression of mature articular chondrocytes
markers (e.g., type II collagen and aggrecan), but also
decrease the expression of catabolic (e.g., MMP-13,
ADAMTS5) and inflammatory (e.g., iNOS) markers in a
dose-dependent manner. Intriguingly, the highest dose of
BM-MSC-derived MPs or exosomes could not only reverse
the OA phenotype of chondrocytes but also could modu-
late anabolic and catabolic chondrocyte markers to a simi-
lar extent as BM-MSCs. Another important finding was
that preactivation of BM-MSCs with TGFβ3 can improve
the effectiveness of both exosomes and MPs. Although the
differences were relatively small in comparison with non-
preactivated BM-MSCs, the gene expression pattern was
significantly different in the MPs or exosomes derived from
pre-activated BM-MSCs [2]. In addition, researchers have
shown that BM-MSCs may contribute to mediate an anti-
fibrotic function [122]. They speculated that TGFβ3 preac-
tivation of BM-MSCs could trigger their anti-fibroblastic
and pro-chondrogenic function via the release of factors
which could be transferred by exosomes and MPs. They
proved the beneficial effects of MPs and exosomes patho-
genic proliferation of fibroblast and skin fibrosis. In aggre-
gate, these studies indicate that the therapeutic potential of
MSCs and their derivative exosomes. These studies further
emphasized that therapeutic potential of MSC-derived
exosomes could largely vary based on their content com-
position and cell of origin in different pathological and
physiological conditions and should be considered for the
therapeutic applications. Recompositioning of exosome
content through ex vivo pretreatment and/or preactivation
of MSCs with different compounds (e.g., TGFβ3) would be
also another interesting therapeutic approach to maximize
anti-OA potential of exosomes.
Conclusions
Exosomes carry out many different functions in organisms
that include repair of tissue injuries, regulation of immune
response, and inhibition of inflammation. Due to their abil-
ity to repair damaged tissues, MSC-derived exosomes have
been widely studied in regenerative medicine. The improve-
ment in tissue homeostasis caused by MSCs can be
produced by cell-to-cell direct interaction and also by secre-
tion of soluble factors. Exosomes are a kind of soluble bio-
logical mediator isolated from MSCs culture media in vitro.
MSC-derived exosomes are generated under both patho-
logical and physiological conditions. They are primary me-
diators of intercellular communications by transferring
mRNAs, lipids, siRNA, proteins, miRNAs, and ribosomal
RNAs to adjacent cells or remote cells. Different disease
models have been studied in MSC-derived exosome experi-
ments. Findings have demonstrated a similarity of function
between MSC-derived exosomes and intact MSCs them-
selves. This review has presented the evidence for MSC-
derived exosomes as a new approach to cell-free treatment
of OA and joint damage. It is clear that numerous add-
itional investigations must be performed to prove the ef-
fectiveness and feasibility of MSC-derived exosomes in the
therapy of OA in patients.
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